Iovance Biotherapeutics Announces Approval of First Clinical Trial Application by Competent Authority in Netherlands for a Phase 2 Trial of LN-145 for the Treatment of Patients with Cervical Cancer

World News: . []

SAN CARLOS Calif Sept 13 2017 GLOBE NEWSWIRE -- Iovance Biotherapeutics Inc NASDAQIOVA a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte TIL technology today announced the approv al of t...

More news and information about Iovance Biotherapeutics, Inc.

Published By:

Globe Newswire: 13:00 GMT Wednesday 13th September 2017

Published: .

Search for other references to "iovance" on SPi News

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
Sector Publishing Intelligence Ltd.
Ground Floor Offices, Little Keep Gate, Barrack Road, Dorchester, Dorset DT1 1AH
Registered in England and Wales number 0751938.
Privacy Policy | Terms and Conditions | Contact Us

Advertising on SPi News: Information For Advertisers